MedTrace Logo

Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment

NCT00935831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-07-27

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of single doses of compound 1278863A in subjects with renal impairment.

Conditions

Interventions

DRUG

GSK1278863A

50mg, 150mg

DRUG

Placebo

matching placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-12
Primary Completion
2010-04-27
Completion
2010-04-27

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935831 on ClinicalTrials.gov